FMP
Acticor Biotech SAS
ALACT.PA
EURONEXT
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
3.99 EUR
0.06 (1.5%)
About
ceo
Dr. Gilles Avenard M.D.
sector
Healthcare
industry
Biotechnology
website
https://acticor-biotech.com
exchange
EURONEXT
Description
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
CIK
N/A
ISIN
FR0014005OJ5
CUSIP
F47715101
Address
Bâtiment Inserm U1148
Phone
33 9 70 46 86 40
Country
FR
Employee
29
IPO Date
Nov 1, 2021
Summary
CIK
-
Exchange
EURONEXT
Industry
Biotechnology
Sector
Healthcare
CUSIP
F47715101
ISIN
FR0014005OJ5
Country
FR
Price
3.99
Beta
-0.38
Volume Avg.
22.97k
Market Cap
62.86M
Shares
-
52-Week
2.72-6.22
DCF
-0.12
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.39
P/B
-
Website
https://acticor-biotech.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ALACT.PA News
It looks like there's no news available.
